Navigation Links
Study Published in Nature Biotechnology Demonstrates Ability of Moderna's Novel Therapeutic Paradigm to Repair and Regenerate Damaged Heart Tissue
Date:9/8/2013

to develop and commercialize its innovative messenger RNA drugs—initially for rare diseases and oncology—while partnering drug candidates in other therapeutic areas in order to rapidly deliver this innovation to patients. Moderna is a privately held company based in Cambridge, Mass. Visit www.modernatx.com to learn more.

For information contact:
Dan Quinn
617-761-6732
Dan.Quinn@fkhealth.com


'/>"/>
SOURCE Moderna Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. iLab Solutions Announces the Results of the 2013 Core Facility Benchmarking Study
2. ResearchMoz.us: Private Healthcare Market - Investigation, Study, Size, Share in Central Europe and Poland and Poland 2013
3. Orexigen Therapeutics Prepares for the Light Study Interim Analysis Based on Direction from Data Monitoring Committee
4. Personalized Medicine Makes Its Way to Pets With Cancer: Morphogenesis and SEVO-Med Team up for a Canine Cancer Field Study, First of Its Kind, Side-Effect-Free Process to Treat Companion Animals
5. Oncopeptides Initiates Phase II Clinical Study with Melflufen in the Treatment of Multiple Myeloma Patients
6. MiMedx Plantar Fasciitis Study Published In The Foot & Ankle International Journal
7. Technical Study: Vertex Pharma Inc., Orexigen Therapeutics Inc., MAKO Surgical Corp., and Alere Inc.
8. BioStorage Technologies Launches INTEGRITY Study to Measure Effect of Time, Temperature and Preparation Methods on DNA and RNA Samples
9. Study Scavenger and CenterWatch Partner to Improve Patient Recruitment, Enrollment and Mobile Access to Clinical Trials with New Study Scavenger Smartphone App
10. VG Energy Chief Scientist Awarded $200,000 AgriLife Grant to Study Lipid Secretion
11. ImmusanT Initiates Study at Joslin Diabetes Center to Investigate Relationship Between Celiac Disease and Type 1 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 The Pittcon Organizing Committee is pleased ... Safety Tech , an e-Journal and producer of ... the second year for the co-location of Food Labs Conference ... provides that the registration fee to attend the two-day Food ...
(Date:1/15/2014)... 2014 Look inside the new Preferred ... the lab, from fluid handling to instruments to supplies. ... when you order. , Preferred Solutions features a ... the L/S® model for precise flow control and dispensing ...
(Date:1/15/2014)... SAN JOSE, California , January 15, 2014 ... antibody-drug conjugates for cancer, today announced the appointment of Thomas ... Reynolds has over 20 years, development experience gained in the ... Genetics. "I am delighted to welcome Tom at ...
(Date:1/15/2014)... 2014 This webinar will focus on ... safety assessment in biosimilars. , Regulatory frameworks are evolving ... development, however the complex nature of biopharmaceuticals makes the ... efficacy extremely challenging. Based on the specific aspects of ...
Breaking Biology Technology:Pittcon Announces Second Year Partnership With Food Safety Tech 2Pittcon Announces Second Year Partnership With Food Safety Tech 3Cole-Parmer Begins 2014 with the Release of Preferred Solutions 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 3Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2
... Laboratories, pathologist, Ronald L. Weiss, MD, MBA, FCAP, received ... Pathologists at CAP ,11, the organization,s annual meeting, held ... the award honors members "who have made a broad ... of pathology." (Logo: http://photos.prnewswire.com/prnh/20110915/SF69370LOGO ) ...
... 2011 NewCardio, Inc., (OTC BB: NWCI) a cardiovascular ... Clinilabs, will utilize QTinno®, NewCardio,s automated cardiac safety solution, ... new drug under development for a central nervous system ... one important aspect of the trial. Clinilabs, ...
... 2011 Orexigen® Therapeutics, Inc. (Nasdaq: OREX ), ... announced financial results for the third quarter of 2011. For ... net loss of $4.6 million, or $0.10 per share, as ... per share, for the third quarter of 2010. As of ...
Cached Biology Technology:ARUP Laboratories' Pathologist, Ronald L. Weiss, MD, Honored With Lifetime Achievement Award for Contributions to Patient Care and Pathology 2Clinilabs will Conduct Phase 1 Trial Using QTinno® 2Clinilabs will Conduct Phase 1 Trial Using QTinno® 3Clinilabs will Conduct Phase 1 Trial Using QTinno® 4Clinilabs will Conduct Phase 1 Trial Using QTinno® 5Orexigen® Therapeutics Reports Third Quarter Financial Results 2Orexigen® Therapeutics Reports Third Quarter Financial Results 3Orexigen® Therapeutics Reports Third Quarter Financial Results 4Orexigen® Therapeutics Reports Third Quarter Financial Results 5
(Date:4/17/2014)... Kessler Foundation has been named awardee of a ... of Defense Spinal Cord Injury Research Program. Gail ... randomized, double-blinded, controlled, multi-site clinical trial, which will ... after spinal cord injury. Dr. Forrest is assistant ... Kessler Foundation. Two additional sites will participate - ...
(Date:4/17/2014)... in about one per eight hundred births, Down syndrome ... genetic cause of intellectual disability. It results from a ... third copy of chromosome 21 (1% of the human ... team in the Department of Genetic Medicine and Development ... published in Nature , shed light on how ...
(Date:4/17/2014)... about eight years ago, Katia Silvera , a postdoctoral ... were on a field trip in a mountainous area in ... never seen before. , Unable to identify it, they contacted ... turned out to be an unnamed species. So Carnevali recently ... "Lophiaris" is the genus name, comprising about 40 species in ...
Breaking Biology News(10 mins):Kessler Foundation awarded Department of Defense grant for spinal cord injury research 2Trisomy 21: How an extra little chromosome throws the entire genome off balance 2Trisomy 21: How an extra little chromosome throws the entire genome off balance 3Orchid named after UC Riverside researcher 2Orchid named after UC Riverside researcher 3
... Angeles, London, New Delhi, Singapore and Washington DC (16 September, ... Journal of Dental Biomechanics (JDB), the second open access ... and the Hindawi Publishing Corporation. The Journal of ... to the study of biomechanics as it relates to dentistry. ...
... More than 125 years ago Charles Darwin first reported ... not the day and this week, scientists are reporting ... These rhythmic growth spurts, and the ability of plants to ... involved in circadian rhythms the "biological clock" genes that ...
... he discovered a gene that controls innate fear in ... the same gene promotes "helicopter mom" behavior in mice. ... female animals to protect newborn pups and interact cautiously ... concentrated in the amygdala, a key region of the ...
Cached Biology News:SAGE-Hindawi launch Journal of Dental Biomechanics 2'Biological clock' genes control plant growth 2No helicopter moms among Rutgers mutant mice 2No helicopter moms among Rutgers mutant mice 3
... ISO 9001:2000 Certified USDA Research Registered OLAW ... Training AALAS Certified Technicians ... GLP Documentation Upon Request Focus ... for all your custom immunology service needs. ...
Human IL-17D Affinity Purified Polyclonal Ab...
BBS/Glycerol/Casein Block and Diluent - 10X Concentrate, 1 L...
... peptide derived from an internal region of ... of rapamycin FRAP RAFT1 RAPT1). Specificity: ... On Western blots it identifies the target ... (positive control: HEK293 cell lysates). Based on ...
Biology Products: